

## MAGELLAN COMPLETE CARE OF VIRGINIA - MEDALLION 4.0

## Service Authorization (SA) Form

## **Growth Hormone**

If the following information is not complete, correct, or legible, the SA process can be delayed.

Please use one form per member.

MEMBER INFORMATION														
Last Name:	First Name:													
Medicaid ID Number:	Date of Birth:													
Gender: Male Female	Is Member Over 18 Years of Age? Yes No													
	is Welliber Over 16 Tears of Age: Tes No													
PRESCRIBER INFORMATION														
Last Name:	First Name:													
NPI Number:														
Phone Number:	Fax Number:													
Is the Drug Prescribed by or in Consultation with a S	Control													
Endocrinologist Nephrologist	pecialty:													
DRUG INFORMATION														
Drug Name/Form:														
Strength:														
Quantity per Day:														
All Growth Hormone medications require the submi	ission of a Clinical Service Authorization													
Preferred Medications:														
Genotropin® Norditropin FlexPro®														
Non-Preferred Medications:														
Humatrope® cartridge/vial Nutropin AQ	Q® NuSpin®													
☐ Omnitrope® cartridge/vial ☐ Saizen® cartri														
Zomacton® vial Zorbtive® via														
If requesting a non-preferred agent, please docume														
(Form continued on next page.)														

Magellan Complete Care of Virginia – Medallion 4.0 website: <u>www.mccofva.com</u>

© 2018–2020, Magellan Health, Inc. All Rights Reserved. Revised: 12/06/2019 | Effective: 01/01/2020

SA Form: Growth Hormone

Me	lember's Last Name:		Member's First Name:												
CR	RITERIA				<u> </u>	1 1		1 1		L					
1.	1. What is the diagnosis?														
	☐ Idiopathic short stature (ISS) ☐ Pediatric growth hormone (GH) deficiency														
	☐ Noonan syndrome (NS) ☐ Familial short stature														
	SHOX deficiency (SHOXD)														
	Adult GH deficiency	⊟ тı	urner syn	drom	ie (TS)										
	Prader Willi syndrome (PWS)	Sł	nort bow	el syr	drome (	SBS), <i>sk</i>	ip to d	iagno	sis se	ctio	n				
	☐ Chronic renal insufficiency ☐ Pediatric chronic kidney disease, <i>skip to diagnosis sec</i> ☐ Other: ☐														
2.	. Is this request for a new start, restart (re-initiation) or continuation of Growth Hormone (GH) therapy?														
	New start, skip to diagnosis section	R	estart, <i>sk</i>	ip to	diagnosi	s sectio	n 🗌	Conti	nuat	ion					
3.	Is the member's growth velocity at least 2 cm	per y	ear while	on G	H therap	y?									
	Yes No														
	Action Required: If YES, please attach docume	entatio	on from i	nedic	al recora	' suppoi	rting gr	owth	velo	city c	of at				
	least 2 cm/year.														
4.	Are the growth plates open?														
	☐ Yes ☐ No														
5.	What is the member's current height? Age: Ye								in	iches	S				
	Action Required: Please attach documentation	on fro	m the me	edical	record o	f currer	nt heigh	it.							
DI	IAGNOSIS AND MEDICAL INFORMATION														
Со	omplete the Following Section(s) Based on the I	Meml	ber's Dia	gnosi	s. Compl	ete All	That A	pply:							
Se	ection A: All Pediatric Indications														
6.	What is the member's pretreatment height an	nd age	??												
	Age: Years Months		He	ight:		incl	nes								
	<b>Action Required:</b> Please attach documentation age at measurement.	n fron	n the me	dical	record sh	owing <sub>l</sub>	oretrea	tmen	t hei <u>c</u>	ght a	ınd				
7.	Which of the following criteria does the memb	ber's p	oretreatn	nent l	neight m	eet?									
	Greater than or equal to 2.25 standard dev	viation	ns (SD) h	. 1 -	1	r			~						
	Greater than or equal to 2.25 standard det	via cioi	13 (30) 0	SIOM .	tne mear	n for ag	e and g	enaei							
	Greater than or equal to 2 standard deviat		• •			_	_								
8.	Greater than or equal to 2 standard deviat	ions (	SD) belov			_	_								
8.	Greater than or equal to 2 standard deviat  What is the member's pretreatment growth verification (SD) below.	ions ( elocit	SD) belov y?	w the	mean fo	r age ai	_								
8.	Greater than or equal to 2 standard deviat  What is the member's pretreatment growth vector of the standard deviation (SD) below the mean for age and gender	ions ( elocit low th	SD) belov y? ne mean f	w the for ag	mean fo	r age ai	nd gen								
8.	Greater than or equal to 2 standard deviat What is the member's pretreatment growth verification (SD) below the mean for age and gender  Action Required: Please attach documentation	ions ( elocit low th	SD) below y? he mean the mean	w the for ag	mean fo e and ge record sh	r age and	nd gend	der							
8.	Greater than or equal to 2 standard deviat  What is the member's pretreatment growth verification (SD) below the mean for age and gender  Action Required: Please attach documentation  At least 2 heights measured by an endocrin	ions ( elocit low th n fron nologi	SD) below y? he mean the men the men ist at leas	w the for ag dical a	mean fo e and ge record sh onths ap	r age and	nd gend either. ta for a	der t leas	t 1 ye						
	Greater than or equal to 2 standard deviat What is the member's pretreatment growth verification (SD) below the mean for age and gender  Action Required: Please attach documentation	ions ( elocit low th n fron nologi	SD) below y? he mean the men the men ist at leas	w the for ag dical a	mean fo e and ge record sh onths ap	r age and	nd gend either. ta for a	der t leas	t 1 ye		s)				

Magellan Complete Care of Virginia – Medallion 4.0 website: <u>www.mccofva.com</u>

© 2018–2020, Magellan Health, Inc. All Rights Reserved. Revised: 12/06/2019 | Effective: 01/01/2020

SA Form: Growth Hormone

Member's Last Name:									Member's First Name:														
Sec	tion E	3: Pe	diatı	ric GH	Defici	iency			1		J				<u> </u>								
9.	Did t lab)	the r of at es	nem : leas	ber ha st 2 GI	ive a G I stimi Io 'YES, µ	6H resultation	spor on te	ests L	FTs?										as d	eteri	mine	d by	the
10.	Y	⁄es			a GH ro lo	·															rocul	t c	
11.	Doe	s the	mei	mber H defi	<i>lease</i> on nave a ciency lo	defir					-						-	-					
12.	Action	es <b>on R</b>	equi		nave b lo YES, p l.																l ana	' IGFE	3P-3
13.		s the ⁄es	mei		nave 2 Io	or m	ore	docı	umer	nted	pitı	uitar	y hoi	mon	ie de	ficier	ncies	othe	er tha	an Gl	<del>1</del> ?		
14.	Y	⁄es			ive an Io ' <i>YES, </i> ‡											neoi	natal	hypo	oglyc	emia	1?		
Sect	tion (	C: Pe	diatı	ic Chr	onic K	(idne	y Di:	seas	e/ Ch	roni	c R	enal	Insu	fficie	encie	S							
	Doe:	s the Creat	mei	mber e clea	nave a ance one greater	iny of of 75	the mL/	follo min,	owing /1.73	g? In	dica	ate a			app Dial	ly: ysis	-	nder	•				
Sec	tion [	): Pe	ediat	ric Ch	ronic	Kidne	ey D	iseas	se														
16.	_		-		new : urther				re-in	_	on) sta		ontii	nuati	-	f GH itinua							
17.		GH ⁄es	thera	·—	evious Io	sly ap	pro	ved f	or th	is m	em	ber?											
18.					er's cu			_															_
			_		Please er que			ocun	nento	ation	fro	om th	ne m	edica	al rec	ord c	of cui	rent	heig	ht.			
19.	Y	⁄es			owth v																		
			-	-	YES, ¡ (Form							ion fi	rom i	medi	cal re	ecord	l sup	porti	ng g	rowt	h vel	ocity	of

Magellan Complete Care of Virginia – Medallion 4.0 website: <u>www.mccofva.com</u>

© 2018–2020, Magellan Health, Inc. All Rights Reserved. Revised: 12/06/2019 | Effective: 01/01/2020

Page 3 of 4

SA Form: Growth Hormone

Member's Last Name:									Member's First Name:										
Section	E: Adult	GH De	ficien	су	<u> </u>	l		<u> </u>	L	ı	<u> </u>		<b>_</b>		1				
20. Do	20. Does the member have irreversible hypothalamic/pituitary structural lesions or ablation?  Yes No If YES, no further questions.																		
	Yes			-			•												
	es the m Yes				ct in G 5, <b>no f</b> u	•													
22. Dic	the me		ave Gl No	defic	ciency	diagn	osed	during	childh	nood	?								
23. Do	<ul> <li>Does the member have 3 or more pituitary hormone deficiencies?</li> <li>Yes</li> <li>No</li> <li>Was the member retested for GH deficiency after an at least 1-month break in GH therapy?</li> </ul>																		
24. Wa	s the mo		eteste No	ed for	GH de	ficien	cy aft	er an a	t leas	t 1-m	onth	brea	k in GH	l thera	ipy?				
25. Wh	5. Which of the following pharmacologic agents was used in a GH stimulation test to measure peak GH levels?  ☐ Insulin ☐ Clonidine ☐ Levodopa ☐ Glucagon ☐ Arginine																		
	GH stimulation test not performed Other:																		
	Action Required: Please attach documentation showing the results of GH stimulation test.																		
	licate the	-								_									
27. Is t	he pretr Yes		t IGF- No	1 leve	l belov	w the I	labora	atory's	range	e of n	ormal	1?							
	ti <mark>on Req</mark> etreatme	uired: <i>F</i>	lease		h docu	mento	ation <sub>.</sub>	from t	he me	dical	recor	d sho	owing t	he me	ember	r's			
Section	F: Short	Bowel	Syndr	ome															
28. Is t	he mem Yes		eiving No	specia	alized	nutriti	ional	suppo	t?										
29. Wi	ll GH be Yes		conju No	nctior	with	optim	al ma	nagen	ent o	f sho	rt bov	vel sy	yndrom	ne?					
30. Ho	w many	months	of GH	thera	py has	the n	nemb	er rece	ived?		moi	nths	N	ot App	olicab	le/New	ı Start		
	ber Sign	•	-	-									Date						
	ature, th rifiable b	•			is the	above	infor	matio	ı is ac	curat	te								
	include /	-				-	-				-		-						
	sion of d				_			_	-		-								
	npleted an Rx Ma		•										•	(111)	or ma	aned to	).		
_	Nest Bro	_					_	ı allı, (	, U IVIč	agella	ali Hea	aitii,	IIIC.						

Magellan Complete Care of Virginia – Medallion 4.0 website: <u>www.mccofva.com</u>

© 2018–2020, Magellan Health, Inc. All Rights Reserved. Revised: 12/06/2019 | Effective: 01/01/2020